News Center

News Center

Dr. Yu Qiang: Striking a balance between stability and innovation to develop high-quality, differentiated products.

Dr. Yu Qiang: Striking a balance between stability and innovation to develop high-quality, differentiated products.

Recently, Shengshi Taikang announced back-to-back approvals for two innovative drug candidates currently in development, marking the start of their global clinical development journey—both applications were submitted simultaneously in China and the U.S. Earlier this January, Shengshi Taikang’s first product, teriflunomide—a treatment for multiple sclerosis—received regulatory approval, officially propelling the company into its commercialization phase. Meanwhile, the company’s new diabetes drug, a DPP-4 inhibitor called fosdegrelin phosphate, has already entered the final stages of its Phase 3 clinical trials.

Time：2022-08-09 15:47

China's first domestically produced teriflunomide tablet hits the market, bringing new hope for ensuring access to treatments for rare diseases.

China's first domestically produced teriflunomide tablet hits the market, bringing new hope for ensuring access to treatments for rare diseases.

Today, the first domestically produced teriflunomide tablet developed by Shengshi Tai has been launched for sale. The initial batch of patients will benefit in key cities such as Beijing, Shanghai, Guangzhou, Chengdu, and Suzhou, with nationwide coverage expected to follow soon, providing a new treatment option and ensuring reliable drug supply for multiple sclerosis patients across China.

Time：2022-08-09 15:27

Shengshi Taikang Completes First China-U.S. Dual-Reporting New Drug Project, Embarking on Its Overseas Journey

Shengshi Taikang Completes First China-U.S. Dual-Reporting New Drug Project, Embarking on Its Overseas Journey

Today, CGT-1881, a CXCR4 antagonist independently developed by Shengshi Taikang, has received approval from the U.S. Food and Drug Administration (FDA) to enter clinical trials. The drug is intended for mobilizing hematopoietic stem cells in patients with blood cancers. This milestone follows the product’s clinical trial approval from China’s National Medical Products Administration (NMPA) back in June of this year, marking Shengshi Taikang’s first-ever dual-regulatory submission—both in China and the U.S.—for a new drug project.

Time：2022-07-12 15:31

Hand in hand, working together—Shengshi Taikang selected as a key innovation team in Gusu

Hand in hand, working together—Shengshi Taikang selected as a key innovation team in Gusu

Today, the official list of selected candidates for the "2022 Gusu Leading Talents Program in Innovation and Entrepreneurship" was unveiled. Among them are Wang Tong, Hao Yan, and Zhao JiaHong—three core members of the executive team from Shengshi Taikang—who have been successfully chosen as part of a highly prestigious, cutting-edge innovation team, thanks to their project titled "Developing Innovative Dual-Target Drugs Using an Integrated Drug Discovery Platform."

Time：2022-07-10 15:34

Triple-action approach tackles solid tumors: Shengshi Taikang’s innovative dual-target drug completes first subject dosing

Triple-action approach tackles solid tumors: Shengshi Taikang’s innovative dual-target drug completes first subject dosing

Today, CGT-6321, a dual-target small-molecule inhibitor independently developed by Shengshi Taikang, completed dosing of the first subject in its Phase I clinical trial. With its highly selective mechanism, the drug is poised to deliver a triple-action approach against solid tumor proliferation, potentially becoming China’s first-in-class innovative therapy in the field of solid tumor treatment.

Time：2022-07-06 15:40

Hello! Let’s get to know each other again.

Hello! Let’s get to know each other again.

A fresh new image, yet the same unwavering初心. Starting today, Shengshi Taikе officially unveils its brand-new logo and comprehensive VI visual identity design. The evolution of any brand requires keeping pace with the times while continuously innovating and optimizing. This is especially true for innovative biopharmaceutical companies, which must constantly upgrade and adapt—whether in response to industry trends, corporate growth, or shifting market demands—to ensure their brand remains dynamic and competitive.

Time：2022-06-22 09:09

Twin blossoms bloom as Shengshi Taike's two Class 1 new drugs receive clinical approval.

Twin blossoms bloom as Shengshi Taike's two Class 1 new drugs receive clinical approval.

Recently, Shengshi Taikang's two Class 1 innovative drugs, developed entirely in-house, have successively received implicit approval from the National Medical Products Administration for clinical trials. The CXCR4 antagonist CGT-1881 is indicated for hematopoietic stem cell mobilization in patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), while CGT-9475, a next-generation ALK inhibitor, holds promise as a potential treatment option for patients who have developed resistance to existing ALK inhibitors.

Time：2022-06-14 09:19

Shengshi Taikang Named to the "2021 Most Influential Companies in Healthcare" List

Shengshi Taikang Named to the "2021 Most Influential Companies in Healthcare" List

Last night, the "2021 China Healthcare and Greater Health Industry Investment & Financing Honor List" was unveiled online, and Shengshi Taikang was proudly named among the Top 50 "2021 Most Influential Companies in Healthcare." Over the past year, Shengshi Taikang achieved remarkable milestones across multiple fronts—making significant breakthroughs in diabetes, rare diseases, and cancer treatment—and secured notable wins at every stage, from research and development through clinical trials to product commercialization.

Time：2022-05-27 09:25

< 1...456...8 >
中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地